---
schema_version: "secwatch.filing_event.v1"
accession: "0000313616-25-000180"
form_type: "8-K"
ticker: "DHR"
cik: "0000313616"
company_name: "DANAHER CORP /DE/"
filed_at: "2025-10-21T23:59:59+00:00"
generated_at: "2026-05-17T03:07:22.482112+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Danaher Q3 2025: EPS $1.27 GAAP, $1.89 adjusted; revenue up 4.5% to $6.1B

## Summary
- Net earnings $908M ($1.27 diluted EPS); non-GAAP adjusted diluted EPS $1.89.
- Revenue $6.1B, up 4.5% YoY; non-GAAP core revenue up 3.0% YoY.
- Operating cash flow $1.7B; non-GAAP free cash flow $1.4B.
- Full-year 2025 adjusted diluted EPS guidance maintained at $7.70-$7.80; core revenue expected low-single-digit growth.
- Cepheid respiratory revenue better-than-anticipated; bioprocessing momentum cited as key driver.

## SEC filing metadata
- accession: 0000313616-25-000180
- form_type: 8-K
- ticker: DHR
- cik: 0000313616
- company_name: DANAHER CORP /DE/
- filed_at: 2025-10-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/313616/000031361625000180/0000313616-25-000180-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/313616/000031361625000180/dhr-20251021.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000313616-25-000180
- JSON: https://secwatch.observer/filing/0000313616-25-000180.json
- Plain text: https://secwatch.observer/filing/0000313616-25-000180.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.